Overview

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Status:
Completed
Trial end date:
2020-04-17
Target enrollment:
Participant gender:
Summary
Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study.
Phase:
Phase 3
Details
Lead Sponsor:
Avillion Development 1 Limited
Pfizer
Treatments:
Imatinib Mesylate
Molecular Mechanisms of Pharmacological Action